INVO Fertility's Losses Mount Amid Strategic Divestitures

Ticker: IVF · Form: 10-Q · Filed: Nov 17, 2025 · CIK: 1417926

Sentiment: bearish

Topics: Fertility Healthcare, Quarterly Earnings, Net Loss, Cash Burn, Discontinued Operations, Strategic Divestiture, Biotechnology

Related Tickers: IVF

TL;DR

**IVF is bleeding cash and its strategic pivot isn't stopping the massive losses; steer clear until they show a path to profitability.**

AI Summary

INVO Fertility, Inc. (IVF) reported a significant net loss of $25,333,069 for the nine months ended September 30, 2025, a substantial increase from the $5,472,345 net loss in the prior year, primarily driven by a $16,452,562 loss on discontinued operations of NTI and a $1,534,517 loss on disposal of NTI. Total revenue increased to $5,257,933 for the nine months ended September 30, 2025, up from $4,846,034 in 2024, with clinic revenue rising to $5,175,870 from $4,763,131. Operating expenses surged to $11,083,033 from $9,507,386, including a $1,397,353 impairment loss. The company's cash position significantly decreased to $355,891 as of September 30, 2025, from $619,520 at December 31, 2024, with net cash used in operating activities at $7,039,692. Strategic changes include the divestiture of NAYA and a focus on INVO Centers and profitable IVF clinics, alongside substantial non-cash activities like a $6,565,000 C-2 to common stock exchange.

Why It Matters

INVO Fertility's escalating net losses and declining cash position signal significant operational challenges, raising red flags for investors regarding its long-term viability and ability to fund its growth strategy. The divestiture of NAYA and the focus on INVO Centers and IVF clinics indicate a strategic pivot, but the immediate financial impact is negative, with a substantial loss from discontinued operations. This could impact employee morale and job security, while customers might face uncertainty regarding service continuity. In a competitive fertility market, IVF's financial instability could weaken its position against larger, more established players, potentially leading to market share erosion and increased scrutiny from regulators.

Risk Assessment

Risk Level: high — The company reported a net loss of $25,333,069 for the nine months ended September 30, 2025, a 362% increase from the prior year, and its cash balance plummeted to $355,891 from $619,520. Net cash used in operating activities was $7,039,692, indicating a severe cash burn rate that threatens its ability to continue operations without significant new financing.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as INVO Fertility's substantial and increasing losses, coupled with a rapidly diminishing cash reserve, indicate severe financial distress. Await clear evidence of successful strategic execution and a tangible path to profitability before considering any investment.

Financial Highlights

debt To Equity
N/A
revenue
$5,257,933
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$25,333,069
eps
N/A
gross Margin
N/A
cash Position
$355,891
revenue Growth
+8.50%

Revenue Breakdown

SegmentRevenueGrowth
Clinic Revenue$5,175,870+8.75%
Total Revenue$5,257,933+8.50%

Key Numbers

Key Players & Entities

FAQ

What were INVO Fertility's total revenues for the nine months ended September 30, 2025?

INVO Fertility's total revenues for the nine months ended September 30, 2025, were $5,257,933, an increase from $4,846,034 in the same period of 2024. This growth was primarily driven by clinic revenue, which rose to $5,175,870.

How did INVO Fertility's net loss change for the nine months ended September 30, 2025?

INVO Fertility's net loss significantly increased to $25,333,069 for the nine months ended September 30, 2025, compared to a net loss of $5,472,345 for the same period in 2024. This represents a 362% increase in net loss.

What was the primary reason for the increased net loss at INVO Fertility?

The primary reason for the increased net loss at INVO Fertility was a substantial loss from discontinued operations, specifically a $16,452,562 loss on discontinued operations of NTI and a $1,534,517 loss on disposal of NTI, totaling over $17.9 million.

What is INVO Fertility's cash position as of September 30, 2025?

As of September 30, 2025, INVO Fertility's cash balance was $355,891. This is a decrease from $619,520 at December 31, 2024, indicating a significant reduction in available cash.

How much cash did INVO Fertility use in operating activities for the nine months ended September 30, 2025?

INVO Fertility used $7,039,692 in net cash from operating activities for the nine months ended September 30, 2025. This is a substantial increase from the $2,357,021 used in the prior year, highlighting an accelerated cash burn.

What strategic changes did INVO Fertility make regarding its assets?

INVO Fertility made strategic changes including the divestiture of NAYA, which resulted in a divestiture amount of $(6,569) in cash flow from investing activities. The company also reported a significant reclassification of Series C-2 Preferred stock and a C-2 to common stock exchange of $6,565,000.

What are the key risks for INVO Fertility investors based on this filing?

Key risks for INVO Fertility investors include the company's substantial and increasing net losses ($25.3 million), rapidly diminishing cash reserves ($355,891), and high cash burn from operating activities ($7.0 million). These factors raise significant concerns about the company's ability to sustain operations and fund future growth.

How many shares of common stock did INVO Fertility have outstanding as of November 17, 2025?

As of November 17, 2025, INVO Fertility had 15,130,282 shares of common stock outstanding. This figure is important for understanding potential dilution for existing shareholders.

What is INVO Fertility's main business strategy?

INVO Fertility's principal commercialization strategy focuses on building, acquiring, and operating fertility clinics, including "INVO Centers" that primarily offer the intravaginal culture (IVC) procedure using its INVOcell medical device, and US-based, profitable in vitro fertilization (IVF) clinics.

Did INVO Fertility have any impairment losses during the nine months ended September 30, 2025?

Yes, INVO Fertility recognized an impairment loss of $1,397,353 for the nine months ended September 30, 2025. This contributed to the overall increase in total operating expenses for the period.

Risk Factors

Industry Context

The fertility industry is characterized by increasing demand driven by delayed childbearing and advancements in reproductive technologies. However, it is also a highly regulated sector with significant competition. Companies like INVO Fertility focus on providing accessible and cost-effective solutions, often through partnerships and innovative service models, but face challenges in scaling operations and managing profitability amidst high operating costs.

Regulatory Implications

The mention of 'Unregistered Sales of Equity Securities' and 'Defaults Upon Senior Securities' as risk factors points to potential regulatory and compliance issues. These could lead to investigations, fines, or legal actions, impacting the company's financial stability and reputation.

What Investors Should Do

  1. Monitor cash burn and operating expenses closely.
  2. Evaluate the impact of discontinued operations and divestitures.
  3. Assess the long-term viability of the current business model.
  4. Understand the implications of equity issuances and potential dilution.

Key Dates

Glossary

Discontinued Operations
A component of a business that the company has disposed of or classified as held for sale, and whose results are reported separately from continuing operations. (A significant loss of $16,452,562 from discontinued operations of NTI heavily impacted the net loss for the period.)
Impairment Loss
A reduction in the carrying value of an asset when its recoverable amount is less than its book value. (An impairment loss of $1,397,353 was included in operating expenses, contributing to the increased cost base.)
C-2 to Common Stock Exchange
A transaction where a specific class of preferred stock (C-2) is converted into common stock of the company. (A $6,565,000 exchange of C-2 stock for common stock is a significant non-cash event that affects equity structure and potential dilution.)
Segment Reporting
Disclosure of financial information about different business segments of a company, allowing for analysis of performance by division. (The company operates in three segments, with clinic revenue being the primary driver of total revenue.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, INVO Fertility has seen a significant increase in its net loss, escalating from $5.5 million to $25.3 million, largely due to substantial losses from discontinued operations. While total revenue saw a modest increase of 8.50% to $5.3 million, driven by clinic revenue growth, operating expenses also surged by approximately 16.6% to $11.1 million, including a notable impairment loss. The company's cash position has weakened considerably, falling from $619,520 at year-end 2024 to $355,891, with operating cash burn intensifying. New risks related to unregistered equity sales and potential defaults on senior securities have emerged, adding to existing operational and financial concerns.

Filing Stats: 4,689 words · 19 min read · ~16 pages · Grade level 19.2 · Accepted 2025-11-17 07:00:43

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited): 4 Consolidated Balance Sheet as of September 30, 2025 (Unaudited) and December 31, 2024 4 Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 5 Consolidated Statements of Stockholders' Equity for the nine months ended September 30, 2025 and 2024 (Unaudited) 6 Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited) 7 Notes to the Consolidated Financial Statements 8 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 3.

Quantitative and Qualitative Disclosures about Market Risks

Quantitative and Qualitative Disclosures about Market Risks 45 4.

Controls and Procedures

Controls and Procedures 45

OTHER INFORMATION

PART II. OTHER INFORMATION 1.

Legal Proceedings

Legal Proceedings 46 1A.

Risk Factors

Risk Factors 46 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 3. Defaults Upon Senior Securities 46 4. Mine Safety Disclosure 46 5. Other Information 46 6. Exhibits 47

Signatures

Signatures 48 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by such forward-looking terminology as "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates, and projections about our company, are not guarantees of future results or performance, and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the following: our business strategies; the timing of regulatory submissions; our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; risks relating to the timing and costs of clinical trials and the timing and costs of other expenses; risks related to market acceptance of products; the ultimate impact of a health epidemic on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; intellectual property risks; risks associated with our reliance on third-party organizati

Business

Business Segments The Company operates in three segments. See "Note 15 – Segment Reporting" for additional information on the Company's segments.

Business

Business Acquisitions The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. Discontinued Operations The Company accounted

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing